Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SELLAS Life Sciences (SLS) EBITDA Margin (2020 - 2022)

Historic EBITDA Margin for SELLAS Life Sciences (SLS) over the last 4 years, with Q1 2022 value amounting to 1673.5%.

  • SELLAS Life Sciences' EBITDA Margin fell 16341100.0% to 1673.5% in Q1 2022 from the same period last year, while for Dec 2022 it was 4195.0%, marking a year-over-year decrease of 38621800.0%. This contributed to the annual value of 4195.0% for FY2022, which is 38621800.0% down from last year.
  • SELLAS Life Sciences' EBITDA Margin amounted to 1673.5% in Q1 2022, which was down 16341100.0% from 234.37% recorded in Q2 2021.
  • SELLAS Life Sciences' EBITDA Margin's 5-year high stood at 39.39% during Q1 2021, with a 5-year trough of 1673.5% in Q1 2022.
  • Over the past 3 years, SELLAS Life Sciences' median EBITDA Margin value was 226.63% (recorded in 2021), while the average stood at 541.54%.
  • The largest annual percentage gain for SELLAS Life Sciences' EBITDA Margin in the last 5 years was -16341100bps (2022), contrasted with its biggest fall of -16341100bps (2022).
  • Over the past 3 years, SELLAS Life Sciences' EBITDA Margin (Quarter) stood at 218.89% in 2020, then dropped by -7bps to 234.37% in 2021, then crashed by -614bps to 1673.5% in 2022.
  • Its EBITDA Margin was 1673.5% in Q1 2022, compared to 234.37% in Q2 2021 and 39.39% in Q1 2021.